Barbero María Asunción Nieto
Servicio de Neumología, Hospital Clínico San Carlos, Facultad de Medicina, Universidad Complutense, Madrid, España.
Arch Bronconeumol. 2009;45 Suppl 4:24-30. doi: 10.1016/S0300-2896(09)72860-1.
Pulmonary hypertension (PHT) is a common complication in chronic respiratory diseases and specifically in chronic obstructive pulmonary disease (COPD), although its prevalence has not been well determined. PHT affects functional capacity and survival in these patients. This complication is usually moderate or mild and develops when airflow obstruction is severe. However, some patients have "disproportionate" PHT, despite minimal functional involvement and optimal treatment. Although alveolar hypoxia has classically been considered to be the main cause, in the last few years other pathogenic mechanisms have been identified, especially those producing vascular remodelling, which are reviewed in the present article. Lastly, the diagnostic approach and therapeutic management of PHT in patients with COPD are analyzed.
肺动脉高压（PHT）是慢性呼吸系统疾病尤其是慢性阻塞性肺疾病（COPD）的常见并发症，尽管其患病率尚未得到确切确定。PHT会影响这些患者的功能能力和生存率。这种并发症通常为中度或轻度，在气流阻塞严重时出现。然而，一些患者尽管功能受累极小且接受了最佳治疗，仍会出现“不成比例的”PHT。虽然传统上认为肺泡缺氧是主要原因，但在过去几年中已发现其他致病机制，尤其是那些导致血管重塑的机制，本文将对此进行综述。最后，分析了COPD患者中PHT的诊断方法和治疗管理。
